ProQR Therapeutics NV（PRQR）股票分析PRQRProQR Therapeutics NV

ProQR Therapeutics N.V. is a biotechnology company based in the Netherlands. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. Main purpose of the Company is advancement of its Axiomer RNA-editing platform technology. That technology uses a cell’s own editing machinery called ADAR to make specific single nucleotide edits in RNA to reverse a mutation or modulate protein expression and could potentially yield a new class of medicines for both rare and prevalent diseases with unaddressed needs. The Company operates research pipeline that contains of RNA Therapy and AX-0810 Cholestatic Diseases (NTCP). It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

ProQR Therapeutics is a good buy right now, trading at $2.29 with a recent analyst price target of $8 from BofA, indicating a potential upside of over 250%. Additionally, the stock has a strong RSI of 60.6, suggesting it is not overbought. The main risk is the negative net income of -13,383,000 EUR in Q1 2026, which reflects ongoing financial challenges.

4 analysts cover PRQR: 3 rate it Buy, 1 Hold and 0 Sell. The average price target is 8.67.